Immunex (Global rights to Leukine) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
2
Immunex (Global rights to Leukine) General Information
Description
An immuno-stimulant drug. The immuno-stimulant drug is a man-made form of granulocyte-macrophage colony-stimulating factor used to help increase the number and function of white blood cells after bone marrow transplantation, in cases of bone marrow transplantation failure or engraftment delay, before and after peripheral blood stem cell transplantation and following induction chemotherapy in older patients with acute myelogenous leukemia.
Contact Information
Website
www.leukine.comCorporate Office
- Boston, MA
- United States
Corporate Office
- Boston, MA
- United States
Immunex (Global rights to Leukine) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Immunex (Global rights to Leukine) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Immunex (Global rights to Leukine) FAQs
-
Where is Immunex (Global rights to Leukine) headquartered?
Immunex (Global rights to Leukine) is headquartered in Boston, MA.
-
What industry is Immunex (Global rights to Leukine) in?
Immunex (Global rights to Leukine)’s primary industry is Buildings and Property.
-
Is Immunex (Global rights to Leukine) a private or public company?
Immunex (Global rights to Leukine) is a Private company.
-
What is Immunex (Global rights to Leukine)’s current revenue?
The current revenue for Immunex (Global rights to Leukine) is .
-
Who are Immunex (Global rights to Leukine)’s investors?
Immunex and Sanofi have invested in Immunex (Global rights to Leukine).
-
When was Immunex (Global rights to Leukine) acquired?
Immunex (Global rights to Leukine) was acquired on 01-Feb-2018.
-
Who acquired Immunex (Global rights to Leukine)?
Immunex (Global rights to Leukine) was acquired by Partner Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process